Oliveira et al. 42 demonstrated that BMCs therapy was able to promote improvement of liver fibrosis resolution associated with decreased liver expression of Gal-3 in a murine model of cirrhosis induced by CCl4. This evidence concerns the gene LGALS3 and Hepatic fibrosis.